Clinical Trial Update: TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Telcyta (TLK286) in combination with carboplatin versus Doxil in platinum-refractory or resistant ovarian cancer has completed recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Doxil (liposomal doxorubicin)
• Telcyta (TLK286)

Snippet

Sponsor: Telik | Conditions: Ovarian Neoplasms | Phase 3 | Status: COMPLETED